Penumbra, Inc.
private/Boston Scientific CorporationBSXBoston Scientific to acquire Penumbra for $374/share in cash and stock
Key takeaways
- Boston Scientific Corporation acquires Penumbra, Inc. — $374 aggregate (mixed).
Deal value
$374
mixed
Per-share offer
—
Premium
—
Days to close
—
Term fee
—
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
May 6, 2026
Expected close
—
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
No advisor data on record for this deal.
- Apr 24, 2026
Boston Scientific to acquire Penumbra in $374/share mixed consideration deal
- Apr 24, 2026this filing
Boston Scientific to acquire Penumbra for $374/share in cash and stock
| Date | Form | Section | Headline | Status |
|---|---|---|---|---|
| Apr 24, 2026 | — | definitive | Boston Scientific to acquire Penumbra in $374/share mixed consideration deal | proxy_filed |
Boston Scientific Corporation agreed to acquire Penumbra Inc in a mixed cash and stock transaction valued at $374.00 per share. Under the merger agreement dated January 14, 2026, Penumbra shareholders may elect to receive either $374.00 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to proration with 73.26% receiving cash and 26.74% receiving stock. The special meeting of Penumbra stockholders is scheduled for May 6, 2026, to vote on the merger.